Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes
M F
MF
Henry Ford Hospital, Detroit, MI 48202.
Venkat
K K
KK
Kupin
W
W
Dumler
F
F
Gracida
C
C
Uniewski
M
M
Anaise
D
D
Tang
D H
DH
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D007902:Length of Stay; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone